U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968988) titled 'Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma' on May 05.
Brief Summary: The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Metastatic Soft-tissue Sarcoma
Intervention:
DRUG: Zanzalintinib
Zanza...